title: Topically Applied Midodrine, 0.2%, an α1-Agonist, for the Treatment of Erythromelalgia.
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, Minnesota.
authors.forename: Mark D P
authors.initials: MD
authors.lastname: Davis
authors.affiliation: Department of Dermatology, Mayo Clinic, Rochester, Minnesota.
authors.forename: Claudia S
authors.initials: CS
authors.lastname: Morr
authors.affiliation: Pharmacy Services, Mayo Clinic, Rochester, Minnesota.
authors.forename: Roger A
authors.initials: RA
authors.lastname: Warndahl
authors.affiliation: Department of Neurology, Mayo Clinic, Rochester, Minnesota.
authors.forename: Paola
authors.initials: P
authors.lastname: Sandroni
mesh_terms: D000287:Administration, Topical; D058646:Adrenergic alpha-1 Receptor Agonists / Q000008:administration & dosage*; D000328:Adult; D000368:Aged; D003937:Diagnosis, Differential; D004305:Dose-Response Relationship, Drug; D004916:Erythromelalgia / Q000175:diagnosis / Q000188:drug therapy* / Q000503:physiopathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D008879:Midodrine / Q000008:administration & dosage*; D012189:Retrospective Studies; D012881:Skin Temperature; D016896:Treatment Outcome
chemical_list: D058646:Adrenergic alpha-1 Receptor Agonists; D008879:Midodrine